abstract: The effect of drugs for @entity6 and @entity4 (ecabet @entity3 , @entity7 , @entity10 , and @entity11 ) on the secretion of mucin-like glycoproteins from @entity0 cornea were investigated in vitro and on a short-term, @entity1 @entity2 model in vivo. For the studies in vitro, cultured @entity0 cornea sections (3 mm diameter) were incubated with radiolabeled @entity5 , rinsed, and then incubated for 30 min in the presence of one of the drugs. The culture media were reacted with Dolichos biflorus agglutinate (DBA)-lectin, and the radioactivity of @entity9 -bound mucin-like glycoproteins was measured. A cytotoxicity assay confirmed that mucin-like glycoproteins had not leaked from damaged cells. For studies in vivo, eye drop vehicle or drops containing gefarnate were instilled in the eyes of nine anesthetized @entity1 , and then the eyes were kept open with specula for two hours. These @entity1 and two control @entity1 not subjected to ocular drying were killed, and their eyes were enucleated and stained with @entity8 . Corneal epithelial damage from desiccation was evaluated based on the extent of @entity8 staining. Among the four kinds of drugs for @entity6 and @entity4 , only gefarnate significantly increased the mucin-like glycoprotein secretion from cultured @entity0 corneas in vitro; this stimulatory effect of gefarnate was dose-dependent. In vivo, the instillation of gefarnate reduced corneal epithelial damage from desiccation in a dose-dependent fashion. These results suggest that gefarnate reduces desiccation of corneal epithelium, perhaps by stimulating secretion of mucin-like glycoproteins from corneal epithelium.

title: XXXX stimulates secretion of mucin-like glycoproteins by corneal epithelium in vitro and protects corneal epithelium from desiccation in vivo.

answer: @entity7


abstract: OBJECTIVE: To inform clinicians of a metastatic orbital @entity3 that frequently masquerades as an orbital inflammatory syndrome and to stimulate thought regarding this @entity3 's fundamental pathobiology specific to its orbital involvement. DESIGN: Interventional case report and literature review. @entity1 : A 47-year-old @entity1 with an acquired, bilateral, diffusely infiltrative orbital process is described. INTERVENTION: The clinical and radiographic features of the @entity1 's orbital process are reported. The review of two prior fine-needle aspiration biopsy specimens failed to reveal a diagnosis. Histopathologic examination of an open surgical biopsy specimen included standard light microscopy of frozen and @entity4 -fixed, @entity5 -embedded tissue. RESULTS: Characteristics light microscopy findings suggested the diagnosis of metastatic @entity6 of the breast. The @entity1 refused all therapeutic intervention and died 9 months after orbitotomy. CONCLUSION: The presentation of @entity0 metastatic to the orbit as a bilateral infiltrative process is far more common than appreciated previously. Its rate of bilateral orbital involvement is 20%, whereas this rate for other @entity3 is much lower. The authors report an additional case, review the clinical features of previous case reports and series, and discuss aspects of the metastatic process. @entity0 must be included in the differential diagnosis of infiltrative orbital processes encountered in adult female @entity1 . When " @entity7 " is detected in an adult female @entity1 , a thorough medical history must be obtained and physical examination performed. If a possible primary @entity0 is indicated, one must be wary of metastatic disease, and a histologic orbital diagnosis is warranted. The frequency of orbital @entity2 and bilateral orbital involvement of this @entity3 reinforces the possibility for organ-specific metastases.

title: Bilateral orbital metastases from XXXX . A case of false pseudotumor.

answer: @entity0


abstract: BACKGROUND: We performed this study to explore the clinical effects of a heterogeneous @entity4 @entity6 ( @entity6 ) used for repairing @entity1 in reconstructive surgery following resection for laryngeal and @entity3 . @entity0 AND METHODS: A summary analysis was carried out on the surgical data of 93 @entity0 who underwent reconstructive surgery using a heterogeneous @entity4 @entity6 following resection of laryngeal and @entity3 . The @entity0 underwent an electronic laryngoscope review. RESULTS: After 3-6 months, the repaired mucosa had replaced the @entity1 in 88 @entity0 who had undergone stage I reconstruction, recovering local function. Due to infection, 3 @entity0 had a laryngeal @entity5 and 2 @entity0 had a pharyngeal @entity5 ; the @entity5 incidence rate was 5.4%. 86 @entity0 underwent successful tracheal extubation (extubation rate, 92.5%). The duration from tracheotomy to extubation was 8-31 days; the average duration was 10.4 days. CONCLUSION: The heterogeneous @entity4 @entity6 is a new, safe, and effective material for reconstructive surgery. In @entity0 with large @entity1 , it avoids the @entity2 caused by flap repair.    2015 S. Karger GmbH, Freiburg.

title: Heterogeneous @entity4 XXXX for mucosal repair in reconstructive surgery for laryngeal and @entity3 .

answer: @entity6


abstract: BACKGROUND: We performed this study to explore the clinical effects of a heterogeneous @entity4 @entity6 ( @entity6 ) used for repairing @entity1 in reconstructive surgery following resection for laryngeal and @entity3 . @entity0 AND METHODS: A summary analysis was carried out on the surgical data of 93 @entity0 who underwent reconstructive surgery using a heterogeneous @entity4 @entity6 following resection of laryngeal and @entity3 . The @entity0 underwent an electronic laryngoscope review. RESULTS: After 3-6 months, the repaired mucosa had replaced the @entity1 in 88 @entity0 who had undergone stage I reconstruction, recovering local function. Due to infection, 3 @entity0 had a laryngeal @entity5 and 2 @entity0 had a pharyngeal @entity5 ; the @entity5 incidence rate was 5.4%. 86 @entity0 underwent successful tracheal extubation (extubation rate, 92.5%). The duration from tracheotomy to extubation was 8-31 days; the average duration was 10.4 days. CONCLUSION: The heterogeneous @entity4 @entity6 is a new, safe, and effective material for reconstructive surgery. In @entity0 with large @entity1 , it avoids the @entity2 caused by flap repair.    2015 S. Karger GmbH, Freiburg.

title: Heterogeneous @entity4 @entity6 for mucosal repair in reconstructive surgery for laryngeal and XXXX .

answer: @entity3


abstract: BACKGROUND: We performed this study to explore the clinical effects of a heterogeneous @entity4 @entity6 ( @entity6 ) used for repairing @entity1 in reconstructive surgery following resection for laryngeal and @entity3 . @entity0 AND METHODS: A summary analysis was carried out on the surgical data of 93 @entity0 who underwent reconstructive surgery using a heterogeneous @entity4 @entity6 following resection of laryngeal and @entity3 . The @entity0 underwent an electronic laryngoscope review. RESULTS: After 3-6 months, the repaired mucosa had replaced the @entity1 in 88 @entity0 who had undergone stage I reconstruction, recovering local function. Due to infection, 3 @entity0 had a laryngeal @entity5 and 2 @entity0 had a pharyngeal @entity5 ; the @entity5 incidence rate was 5.4%. 86 @entity0 underwent successful tracheal extubation (extubation rate, 92.5%). The duration from tracheotomy to extubation was 8-31 days; the average duration was 10.4 days. CONCLUSION: The heterogeneous @entity4 @entity6 is a new, safe, and effective material for reconstructive surgery. In @entity0 with large @entity1 , it avoids the @entity2 caused by flap repair.    2015 S. Karger GmbH, Freiburg.

title: Heterogeneous XXXX @entity6 for mucosal repair in reconstructive surgery for laryngeal and @entity3 .

answer: @entity4


abstract: UNASSIGNED: Serum exosomal microRNAs (miRNAs) have received considerable attention as potential biomarkers for @entity1 diagnosis. Reverse transcription  -quantitative polymerase chain reaction (RT  -qPCR) is commonly used to detect miRNA expression levels in various types of @entity1 . One prerequisite for valid RT  -qPCR data is the correct normalization of miRNAs to stably expressed endogenous reference genes (RGs). The study of @entity2 resection requires the use of reliable RGs in order to assess the expression levels of serum exosomal target miRNAs. However, the assessment of RG suitability for optimum serum exosomal miRNA expression analysis has yet to be investigated. The present study investigated the expression stability of 10 candidate RGs. The candidate genes included eight miRNAs ( @entity6 , @entity5  -103, @entity9 , let  -7a, @entity8 , @entity4 , @entity5  -181a, and @entity7 ) and two small RNAs (5S and U6). The stability values of the candidate genes were calculated using the following algorithms: geNorm, NormFinder, BestKeeper, and the comparative   Ct method. The overall ranking obtained from these analyses revealed that @entity4 , let  -7a, and @entity8 were appropriate internal RGs for analysis of serum miRNAs in @entity0 with @entity3 . In addition, normalization with @entity4 and let  -7a combined, as recommended by geNorm, or with @entity8 , as recommended by NormFinder, increased the accuracy of interpretation of the target miRNA expression levels in hepatopathy studies.

title: Assessment of endogenous reference gene suitability for serum exosomal microRNA expression analysis in XXXX resection studies.

answer: @entity2


abstract: This snapshot reviews the current state of knowledge on genetic variants of nuclear receptors (NRs) involved in regulating various aspects of liver metabolism. Interindividual differences in responses to diet and other 'in-' and environmental stressors can be caused by variants in components of the NR regulatory gene network. We recapitulate recent evidence for the application of NRs in genetic diagnosis of monogenic @entity4 . Genetic analysis of multifactorial @entity4 , such as @entity5 and @entity1 , pinpoints key players in disease predisposition and progression. In particular, @entity8 variants have been associated with @entity10 of pregnancy and @entity9 . Other examples include studies of @entity11 and @entity12 polymorphisms in @entity0 with @entity2 and @entity7 variation in @entity3 . Associations of NR gene variants have been identified in @entity0 with @entity6 and other metabolic syndrome-associated traits by genome-wide studies. Evidence from these analyses confirms a role for NR variation in common diseases, linking regulatory networks to complex and variable phenotypes. These new insights into the impact of NR variants offer perspectives for their future use in diagnosis and treatment of common diseases.    2015 S. Karger AG, Basel.

title: Nuclear receptor variants in XXXX .

answer: @entity4


abstract: BACKGROUND: The aim of the study was to describe the profile of @entity0 and the characteristics of all @entity4 caused by multidrug-resistant (MDR) bacterial strains in a teaching hospital and to assess the mortality related to these events. METHODS: A monocentric retrospective observational cohort study was conducted. All @entity0 with @entity4 caused by MDR bacteria between 2011 and 2013 were included. The characteristics of @entity0 and @entity4 , antibiotic therapy within the first day, and 30-day mortality were collected from the electronic medical records database. RESULTS: A total of 228 @entity0 were included with @entity4 caused by Enterobacteriaceae-producing extended-spectrum b-lactamase (n  =  102), Enterobacteriaceae overproducing AmpC b-lactamase (n  =  59), @entity6 -resistant Enterobacteriaceae (n  =  3), @entity9 - or @entity6 -resistant @entity7 (n  =  2), @entity9 - or @entity6 -resistant @entity2 (n  =  23), @entity8 -resistant @entity1 (n  =  40), and @entity3 -resistant Enterococcus (n  =  2). The median Charlson comorbidity score was 6. Inappropriate antibiotic therapy was prescribed in 41.7% of @entity4 , and 30-day mortality was 23%. For 20.9% of the @entity0 who had had a positive bacteriologic sample in the preceding 2  months, the initial antibiotic therapy was inappropriate. CONCLUSION: In this cohort of @entity4 @entity0 , a high rate of mortality and numerous @entity0 comorbidities were observed. Taking greater account of antecedents of MDR @entity5 could improve the rate of appropriate initial antibiotic therapy.

title: XXXX caused by multidrug-resistant bacteria in a French university hospital center: 3  years of collection.

answer: @entity4


abstract: BACKGROUND: Under the ACA, new programs are being developed to enhance care coordination and reduce health care costs among @entity0 with @entity1 , disabilities, and high utilization of health care. However, the relationships between these groups are not well understood. OBJECTIVES: Our aims were to (1) identify high utilizers of health care in the U.S. working age (18-64) population, (2) examine the overlap between this group and @entity0 with @entity1 and/or disabilities, (3) identify predictors of high service use or cost among these subpopulations, and (4) recommend approaches for stratification of individuals with high health care utilization. METHODS: Using pooled national data from the Medical Expenditure Panel Survey (2006-2008), we created indices to identify elevated or high utilization and cost groups. We performed descriptive analyses, bivariate comparisons and multivariate analyses to examine the relations between these populations and individuals with @entity1 and/or disabilities. RESULTS: While the large majority of @entity0 with high use/cost had @entity1 , the minority of @entity0 with @entity1 had high health care utilization. However, among @entity0 with @entity1 , disability was a significant predictor of high utilization. Annual expenditures were significantly elevated among @entity0 with disabilities, particularly when activities of daily living were limited. CONCLUSIONS: We conclude that medical diagnosis alone is insufficient for the development of eligibility criteria for, or the evaluation of, programs intended to better the delivery or coordination of services for high utilizers of health care services. New approaches are needed to assess functional limitations and identify ongoing needs for services and supports.

title: Diagnosis isn't enough: Understanding the connections between high health care utilization, XXXX and disabilities among U.S. working age adults.

answer: @entity1


abstract: Overexpression and amplification of several genes ( @entity6 , @entity7 and SAS) located on chromosome 12q13-15 have been noted to occur in various @entity0 @entity2 . As a result, two major growth regulation pathways may be inhibited. @entity6 may down regulate the @entity4 -mediated growth control and @entity7 may affect @entity5 -mediated events. To determine the frequency of alterations in these genes and their correlation with clinicopathologic features, we analyzed the @entity6 and @entity7 protein levels by immunohistochemistry and assessed @entity6 , @entity7 and SAS amplification by real-time PCR in nine @entity3 of the jaws. Positive staining for @entity7 and @entity6 was observed in eight cases (88.8%) and five cases (55.5%), respectively. Intense @entity7 staining was noted in four cases (two high grade, one intermediate grade and one low grade). Intense @entity6 staining was observed in the same four previous cases, as well as, one additional high-grade @entity1 . Individual DNA amplification for @entity7 , @entity6 and SAS was observed in six cases for each gene. Co-amplification was observed in five cases that showed @entity7 and @entity6 concomitant amplification and four cases that displayed amplification for all of the genes. In addition, among the five cases that presented @entity7 and @entity6 amplification, strong overexpression of @entity7 and @entity6 was observed in three and in four cases, respectively (three high grade and one intermediate grade). These results suggest that 12q13-15 genes are involved in @entity1 and concurrent amplification and overexpression of these genes might help to define high-grade @entity1 .

title: Amplification and protein expression of chromosome 12q13-15 genes in XXXX of the jaws.

answer: @entity3


abstract: AIMS: Therapeutic approaches to treat @entity3 ( @entity3 ), which is characterized by @entity2 and susceptibility to @entity1 -related @entity4 , have been generally unsuccessful. Our objective in the present work was to determine the effect of the @entity7 ( @entity7 ) biased ligand, @entity9 , on contractility of hearts of a transgenic @entity0 model of @entity3 with mutation in tropomyosin at position 54 (TG- @entity8 ). Our rationale is based on previous studies, which have supported the hypothesis that biased G-protein-coupled receptor ligands, signalling via b-arrestin, increase cardiac contractility with no effect on @entity1 transients. Our previous work demonstrated that the biased ligand @entity9 is able to block angiotensin-induced @entity5 , while promoting an increase in sarcomere @entity1 response. METHODS AND RESULTS: We tested the hypothesis that the @entity2 in cardiac function associated with @entity3 can be offset by infusion of the @entity7 biased ligand, @entity9 . We intravenously infused saline, @entity9 , or the unbiased ligand, @entity6 , for 15 min in TG- @entity8 and non- @entity0 to obtain left ventricular pressure-volume relations. Hearts were analysed for sarcomeric protein phosphorylation. Results showed that the @entity7 biased ligand increases cardiac performance in TG- @entity8 @entity0 in association with increased myosin light chain-2 phosphorylation. CONCLUSION: Treatment of @entity0 with an @entity7 biased ligand, acting via b-arrestin signalling, is able to induce an increase in cardiac contractility associated with an increase in ventricular myosin light chain-2 phosphorylation. @entity7 biased ligands may prove to be a novel inotropic approach in @entity3 .

title: Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, XXXX , in a @entity3 model.

answer: @entity9


abstract: AIMS: Therapeutic approaches to treat @entity3 ( @entity3 ), which is characterized by @entity2 and susceptibility to @entity1 -related @entity4 , have been generally unsuccessful. Our objective in the present work was to determine the effect of the @entity7 ( @entity7 ) biased ligand, @entity9 , on contractility of hearts of a transgenic @entity0 model of @entity3 with mutation in tropomyosin at position 54 (TG- @entity8 ). Our rationale is based on previous studies, which have supported the hypothesis that biased G-protein-coupled receptor ligands, signalling via b-arrestin, increase cardiac contractility with no effect on @entity1 transients. Our previous work demonstrated that the biased ligand @entity9 is able to block angiotensin-induced @entity5 , while promoting an increase in sarcomere @entity1 response. METHODS AND RESULTS: We tested the hypothesis that the @entity2 in cardiac function associated with @entity3 can be offset by infusion of the @entity7 biased ligand, @entity9 . We intravenously infused saline, @entity9 , or the unbiased ligand, @entity6 , for 15 min in TG- @entity8 and non- @entity0 to obtain left ventricular pressure-volume relations. Hearts were analysed for sarcomeric protein phosphorylation. Results showed that the @entity7 biased ligand increases cardiac performance in TG- @entity8 @entity0 in association with increased myosin light chain-2 phosphorylation. CONCLUSION: Treatment of @entity0 with an @entity7 biased ligand, acting via b-arrestin signalling, is able to induce an increase in cardiac contractility associated with an increase in ventricular myosin light chain-2 phosphorylation. @entity7 biased ligands may prove to be a novel inotropic approach in @entity3 .

title: Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, @entity9 , in a XXXX model.

answer: @entity3


abstract: The differential, tissue-specific regulation of @entity3 (OT) binding sites allows the neurohypophysial nonapeptide OT to fulfill a dual role: to induce uterine contractions at parturition and to mediate milk ejection during lactation. Whereas uterine OT binding sites are up-regulated prior to parturition and are rapidly down-regulated thereafter, mammary gland OT binding sites gradually increase throughout gestation and remain up-regulated during the ensuing lactation period. Here, we structurally characterized @entity6 ( @entity6 ) mRNA in mammary gland and analyzed its expression during gestation and lactation and in response to @entity1 treatment. In mammary gland tissues, we found a 6.7 and a 5.4 kb @entity6 mRNA species, and both species were further analyzed by RACE (rapid amplification of cDNA ends). The 6.7 kb mRNA was found to be common to mammary gland and uterus and to extend 618 @entity5 beyond the published sequence of the @entity0 @entity6 gene. The 5.4 kb mRNA species is unique to the mammary gland and terminates at a mammary gland-specific polyadenylation site that is not preceded by a classical polyadenylation signal. RT-PCR analysis did not provide any evidence for differences in the coding regions, suggesting that both uterine and mammary gland @entity6 mRNAs encode the same receptor protein. Furthermore, primer extension experiments showed that no differences exist in the specific transcriptional initiation sites of the @entity6 gene in the two tissues. During pregnancy, @entity6 mRNA per mammary gland increased approximately 150-fold and remained high during lactation, consistent with the previously identified regulation of OT binding sites and the role of OT during lactation. Whereas @entity2 administration strongly induced the uterine @entity6 mRNA levels (>5-fold), mammary gland remained unaffected by @entity1 treatment. Moreover, @entity4 had no effect on the mammary gland @entity6 mRNA level. In summary, our data demonstrate a differential control of @entity6 expression in uterus versus mammary gland and a mammary gland-specific @entity6 mRNA polyadenylation site. However, this differential control apparently does not involve the expression of different receptor genes nor the utilization of tissue-specific transcriptional initiation sites.

title: XXXX receptor gene expression in @entity0 mammary gland: structural characterization and regulation.

answer: @entity3


abstract: The differential, tissue-specific regulation of @entity3 (OT) binding sites allows the neurohypophysial nonapeptide OT to fulfill a dual role: to induce uterine contractions at parturition and to mediate milk ejection during lactation. Whereas uterine OT binding sites are up-regulated prior to parturition and are rapidly down-regulated thereafter, mammary gland OT binding sites gradually increase throughout gestation and remain up-regulated during the ensuing lactation period. Here, we structurally characterized @entity6 ( @entity6 ) mRNA in mammary gland and analyzed its expression during gestation and lactation and in response to @entity1 treatment. In mammary gland tissues, we found a 6.7 and a 5.4 kb @entity6 mRNA species, and both species were further analyzed by RACE (rapid amplification of cDNA ends). The 6.7 kb mRNA was found to be common to mammary gland and uterus and to extend 618 @entity5 beyond the published sequence of the @entity0 @entity6 gene. The 5.4 kb mRNA species is unique to the mammary gland and terminates at a mammary gland-specific polyadenylation site that is not preceded by a classical polyadenylation signal. RT-PCR analysis did not provide any evidence for differences in the coding regions, suggesting that both uterine and mammary gland @entity6 mRNAs encode the same receptor protein. Furthermore, primer extension experiments showed that no differences exist in the specific transcriptional initiation sites of the @entity6 gene in the two tissues. During pregnancy, @entity6 mRNA per mammary gland increased approximately 150-fold and remained high during lactation, consistent with the previously identified regulation of OT binding sites and the role of OT during lactation. Whereas @entity2 administration strongly induced the uterine @entity6 mRNA levels (>5-fold), mammary gland remained unaffected by @entity1 treatment. Moreover, @entity4 had no effect on the mammary gland @entity6 mRNA level. In summary, our data demonstrate a differential control of @entity6 expression in uterus versus mammary gland and a mammary gland-specific @entity6 mRNA polyadenylation site. However, this differential control apparently does not involve the expression of different receptor genes nor the utilization of tissue-specific transcriptional initiation sites.

title: @entity3 receptor gene expression in XXXX mammary gland: structural characterization and regulation.

answer: @entity0


abstract: UNASSIGNED: A 59-year-old Hispanic @entity0 presented with a 3-year history of floaters associated with bilateral reduced visual acuity. Her best-corrected visual acuity (BCVA) was 20/40. Both anterior segments were without @entity1 , but fundoscopy showed mild @entity1 and multiple inflammatory @entity2 . Tests for inflammatory and infectious diseases were negative except for human leucocyte antigen A29. The @entity0 was diagnosed with birdshot choroidoretinopathy, and treatment was initiated with @entity3 2.5   mg/kg/day. One year after treatment, the @entity0 reported systemic symptoms with no improvement in visual acuity. Fundus findings remained with @entity1 . QuantiFERON- @entity4 Gold In-Tube Test was positive, and a diagnosis of presumed latent @entity5 ( @entity4 ) was made. We initiated anti- @entity4 treatment for 9   months. At 6   months of anti- @entity4 therapy, there was no active @entity1 . The @entity0 was followed for 2   years with no medications and no active @entity1 . Her final BCVA was 20/25.

title: Presumed latent @entity5 diagnosed with the positive quantiFERON- XXXX Gold In-Tube Test in a HLA-A29-positive @entity0 .

answer: @entity4


abstract: UNASSIGNED: A 59-year-old Hispanic @entity0 presented with a 3-year history of floaters associated with bilateral reduced visual acuity. Her best-corrected visual acuity (BCVA) was 20/40. Both anterior segments were without @entity1 , but fundoscopy showed mild @entity1 and multiple inflammatory @entity2 . Tests for inflammatory and infectious diseases were negative except for human leucocyte antigen A29. The @entity0 was diagnosed with birdshot choroidoretinopathy, and treatment was initiated with @entity3 2.5   mg/kg/day. One year after treatment, the @entity0 reported systemic symptoms with no improvement in visual acuity. Fundus findings remained with @entity1 . QuantiFERON- @entity4 Gold In-Tube Test was positive, and a diagnosis of presumed latent @entity5 ( @entity4 ) was made. We initiated anti- @entity4 treatment for 9   months. At 6   months of anti- @entity4 therapy, there was no active @entity1 . The @entity0 was followed for 2   years with no medications and no active @entity1 . Her final BCVA was 20/25.

title: Presumed latent XXXX diagnosed with the positive quantiFERON- @entity4 Gold In-Tube Test in a HLA-A29-positive @entity0 .

answer: @entity5


abstract: UNASSIGNED: A 59-year-old Hispanic @entity0 presented with a 3-year history of floaters associated with bilateral reduced visual acuity. Her best-corrected visual acuity (BCVA) was 20/40. Both anterior segments were without @entity1 , but fundoscopy showed mild @entity1 and multiple inflammatory @entity2 . Tests for inflammatory and infectious diseases were negative except for human leucocyte antigen A29. The @entity0 was diagnosed with birdshot choroidoretinopathy, and treatment was initiated with @entity3 2.5   mg/kg/day. One year after treatment, the @entity0 reported systemic symptoms with no improvement in visual acuity. Fundus findings remained with @entity1 . QuantiFERON- @entity4 Gold In-Tube Test was positive, and a diagnosis of presumed latent @entity5 ( @entity4 ) was made. We initiated anti- @entity4 treatment for 9   months. At 6   months of anti- @entity4 therapy, there was no active @entity1 . The @entity0 was followed for 2   years with no medications and no active @entity1 . Her final BCVA was 20/25.

title: Presumed latent @entity5 diagnosed with the positive quantiFERON- @entity4 Gold In-Tube Test in a HLA-A29-positive XXXX .

answer: @entity0


abstract: @entity0 and work: a compatible system? Problems of health and disease associated with work. Here, a short review of the main characteristics of the modern work organisation and of its influences on worker's health is reported. In spite of the great improvement that has occurred in the environment and in the relationships between employers and employees, many conflicts and @entity3 are still present, about ecological, insurance and economical problems, often on an international ground. In addition work organisation is mostly perceived as unable to satisfy personal needs, attitudes and values. That is true even in industrialised countries, where 60-70% of active population is engaged in office job. While the expansion of tertiary sector has greatly contributed to the decrease of @entity4 , sick leave, due to non-specific symptoms and complaints related to prevalent chronic @entity2 , has increased. The frequently observed relationship between such disorders, mostly with a strong phycophysiological component, has produced the designation of "job @entity1 ". Tackling these together with the traditional occupational health problems implies a revision of methods and contents of occupational medicine and its connection with related preventive and clinical disciplines. The international debate on the issue may offer useful suggestions for the Italian situation.

title: [ XXXX and work: a compatible system? Problems of health and disease associated with work].

answer: @entity0


abstract: BACKGROUND: Carotid-femoral @entity1 (cfPWV) is a well-established measure of central arterial stiffness, while brachial-ankle @entity1 (baPWV) is being used more frequently in East Asian countries. Few studies have simultaneously characterized the distributions and correlates of segment-specific @entity1 measures and their associations with cardiovascular risk factors. METHODS: We evaluated segment-specific @entity1 (cfPWV, baPWV, and femoral-ankle (faPWV)) in 4,974 older-aged African American and Caucasian adults in the community-based @entity4 Risk in Communities (ARIC) Study using a standardized protocol and the OMRON VP-1000 Plus system. We examined the distribution and multivariable-adjusted correlates of @entity1 measures by race and sex. RESULTS: Mean age ranged from 74  5 to 76  5 years across race-sex groups. In all race-sex groups, cfPWV correlated with baPWV but not with faPWV, and cfPWV and baPWV were higher with age, whereas faPWV was not. Heart rate and systolic blood pressure (SBP) were positively associated and weight was negatively associated with all @entity1 measures; however, the associations with age, glycated hemoglobin, @entity5 , and high-density lipoprotein (HDL) @entity2 varied by segment and race-sex group. CONCLUSIONS: Our findings indicate that cfPWV and faPWV reflect distinct aspects of segment-specific @entity3 and their associated profile of cardiovascular risk factors. Even among older adults, age is associated with higher cfPWV and baPWV, but not with faPWV. Understanding factors that ostensibly play a role in increasing arterial stiffness in different arterial territories can inform opportunities for @entity0 ( @entity0 ) prevention and risk management.

title: Correlates of Segmental Pulse Wave Velocity in Older Adults: The XXXX Risk in Communities (ARIC) Study.

answer: @entity4


abstract: BACKGROUND: In the current era, most @entity9 deaths occur in @entity0 <3 months of age. @entity7 with @entity10 and @entity1 are commonly observed among cases of severe @entity9 . METHODS: Risk factors associated with fatal @entity9 were identified by comparing fatal @entity9 cases among @entity0 <120 days of age occurring from 1 January 1998 through 26 December 2014, matched by age (<120 days), county of residence, and closest symptom onset date with 1-4 nonfatal hospitalized cases. California Department of Public Health surveillance data were reviewed to identify cases; demographics, clinical presentation, and course were abstracted from corresponding birth and medical records. Logistic regression and classification tree analyses were used to examine the risk of fatal @entity9 with respect to identified factors. RESULTS: Fifty-three fatal @entity0 @entity9 cases were identified and compared with 183 nonfatal hospitalized @entity9 cases. Fatal cases had significantly lower birth weight, younger gestational age, younger age at time of cough onset, and higher peak white blood cell (WBC) and lymphocyte counts. Fatal cases were less likely to have received @entity11 antibiotics and more likely to have received @entity5 or @entity8 and to develop @entity2 , @entity6 , @entity3 , and @entity1 . Additionally, exchange transfusion, extracorporeal membrane oxygenation, and intubation occurred significantly more frequently among fatal cases. In multivariate analyses, peak WBC count, birth weight, intubation, and receipt of @entity8 were predictors of @entity4 . CONCLUSIONS: Early recognition of @entity9 in young @entity0 and treatment with appropriate antibiotic therapy are important in preventing @entity4 . Several risk factors are strongly associated with fatal @entity9 in @entity0 .

title: Risk Factors Associated With XXXX Deaths From Pertussis: A Case-Control Study.

answer: @entity0


abstract: @entity2 mediates the antierectile role of the sympathetic nervous system. It binds to postsynaptic alpha 1 adrenoceptors present on smooth muscle fibers of the corpus cavernosum. Receptor cloning studies have evidenced three alpha 1 adrenoceptor subtypes: alpha 1A, alpha 1B and alpha 1D. We searched for the presence of these three alpha 1 adrenoceptor subtypes in the @entity0 corpus cavernosum using in situ hybridization with specific oligonucleotide probes. Brain tissue was used as the reference of probes specificity. Autoradiographic films were studied with light illumination and computer-assisted densitometry using an image analyser. We provide evidence that the three alpha 1 adrenoceptor subtypes are expressed in the @entity0 corpus cavernosum. These three subtypes appear to be more expressed in the trabecular smooth muscle fibers than in vascular smooth muscle fibers. Further experiments are needed to determine whether the proportion of alpha 1 adrenoceptor subtypes changes according to the etiology of @entity1 . This morphological approach provides a basis for future pharmacological research of specific alpha 1 adrenoceptor subtypes blocking agents designed to treat @entity1 .

title: Expression of alpha 1 adrenoceptor subtypes in XXXX corpus cavernosum.

answer: @entity0


abstract: RATIONALE AND OBJECTIVES: The authors assessed the sequential sonographic and computed tomographic (CT) findings and their correlations with pathologic findings of the normal @entity4 liver after percutaneous @entity7 injection ( @entity8 ). METHODS: In 30 anesthetized @entity4 , 1 mL of @entity7 was injected percutaneously under sonographic guidance. The animals were divided into five groups of six @entity4 each according to the times of sonography and CT examinations after @entity8 : day 1 (immediately after), day 3, week 1, week 2, and week 4. The radiologic findings were analyzed regarding echogenicity (sonography) and density patterns before and after contrast administration (CT). The relations between radiologic findings and pathologic findings were examined using statistical analysis. The lesion size was measured using sonography and CT and compared with the actual size of the pathologic specimen. RESULTS: Sonography and CT showed various radiologic findings according to the time elapsed after @entity8 . The livers were hyperechoic in 100% (6/6) of the @entity4 on day 1; this changed to isoechoic (67%, 12/18) or slightly hypoechoic (22%, 4/18) after week 1 through week 4 after @entity8 on sonography. CT scanning showed well-defined, hypodense lesions with no contrast enhancement in 100% (6/6) of the @entity4 on day 1, and the lesions were slightly hypodense and relatively poorly defined in 88% (21/24) after day 3. Peripheral enhancement was noted in 83% (15/18) after week 1. Histopathologic examination revealed @entity6 and @entity5 correlating well with hyperechogenicity on sonography and very low density on CT immediately after @entity8 . Coagulation @entity1 was a main pathologic finding in the central portion of the lesions after day 3 and correlated with the CT findings of central low density without contrast enhancement. After week 1, peripheral granulation tissue and @entity3 were correlated with peripheral contrast enhancement on CT. Lesion size was largest in the week 1 group, and the size difference was statistically significant between the week 1 group and the day 1 group. CONCLUSIONS: Sonographic and CT findings of the @entity8 -treated normal @entity4 liver varied with time in a predictable manner and correlated with pathologic findings. After a week, the @entity8 -treated normal liver shows perilesional enhancement that is nodular and irregular (particularly until 2 weeks); this must be taken into account when evaluating the therapeutic effect after @entity8 using conventional CT studies. Although long-term data are missing, control CT scans for @entity2 should not be performed before the second week after @entity8 because of the difficulty discerning enhancing @entity0 from enhancing @entity3 .

title: Sequential changes of sonographic and computed tomography findings in the normal XXXX liver after percutaneous @entity7 injection. Correlation with pathologic findings.

answer: @entity4


abstract: RATIONALE AND OBJECTIVES: The authors assessed the sequential sonographic and computed tomographic (CT) findings and their correlations with pathologic findings of the normal @entity4 liver after percutaneous @entity7 injection ( @entity8 ). METHODS: In 30 anesthetized @entity4 , 1 mL of @entity7 was injected percutaneously under sonographic guidance. The animals were divided into five groups of six @entity4 each according to the times of sonography and CT examinations after @entity8 : day 1 (immediately after), day 3, week 1, week 2, and week 4. The radiologic findings were analyzed regarding echogenicity (sonography) and density patterns before and after contrast administration (CT). The relations between radiologic findings and pathologic findings were examined using statistical analysis. The lesion size was measured using sonography and CT and compared with the actual size of the pathologic specimen. RESULTS: Sonography and CT showed various radiologic findings according to the time elapsed after @entity8 . The livers were hyperechoic in 100% (6/6) of the @entity4 on day 1; this changed to isoechoic (67%, 12/18) or slightly hypoechoic (22%, 4/18) after week 1 through week 4 after @entity8 on sonography. CT scanning showed well-defined, hypodense lesions with no contrast enhancement in 100% (6/6) of the @entity4 on day 1, and the lesions were slightly hypodense and relatively poorly defined in 88% (21/24) after day 3. Peripheral enhancement was noted in 83% (15/18) after week 1. Histopathologic examination revealed @entity6 and @entity5 correlating well with hyperechogenicity on sonography and very low density on CT immediately after @entity8 . Coagulation @entity1 was a main pathologic finding in the central portion of the lesions after day 3 and correlated with the CT findings of central low density without contrast enhancement. After week 1, peripheral granulation tissue and @entity3 were correlated with peripheral contrast enhancement on CT. Lesion size was largest in the week 1 group, and the size difference was statistically significant between the week 1 group and the day 1 group. CONCLUSIONS: Sonographic and CT findings of the @entity8 -treated normal @entity4 liver varied with time in a predictable manner and correlated with pathologic findings. After a week, the @entity8 -treated normal liver shows perilesional enhancement that is nodular and irregular (particularly until 2 weeks); this must be taken into account when evaluating the therapeutic effect after @entity8 using conventional CT studies. Although long-term data are missing, control CT scans for @entity2 should not be performed before the second week after @entity8 because of the difficulty discerning enhancing @entity0 from enhancing @entity3 .

title: Sequential changes of sonographic and computed tomography findings in the normal @entity4 liver after percutaneous XXXX injection. Correlation with pathologic findings.

answer: @entity7


abstract: We have reported that @entity0 autoantibodies reacting with the polymorphonuclear neutrophil (PMN)-anchored @entity8 ( @entity9 ) protect these cells from spontaneous apoptosis. In this study, we used anti- @entity9 F(ab')(2) to delineate the mechanism(s) whereby the PMN life span is extended. As documented using four methods, @entity9 cross-linking impeded spontaneous apoptosis, whereas anti- @entity5 F(ab')(2) exerted no effect. Incubation of PMNs with anti- @entity9 prevented the up-regulation of @entity12 integrins, particularly @entity11 , which is the alpha-chain of complement receptor type 3, but also @entity5 , which is its beta-chain, as well as @entity4 and @entity7 . Anti- @entity9 -conditioned supernatant of PMNs diminished the percentage of @entity10 -binding fresh PMNs after another 18 h in culture, whereas the negative control anti- @entity5 had no effect. The expression of mRNA for @entity3 and @entity6 was induced by anti- @entity9 , followed by the release of @entity3 and @entity6 in a dose-dependent manner. Anti- @entity3 and anti- @entity6 mAbs abrogated the antiapoptotic effect of the related growth factors. The delay in apoptosis was accompanied by a down-regulated expression of @entity2 , and a partial reduction of @entity1 activity. These data suggest an autocrine involvement of anti- @entity9 -induced survival factors in the rescue of PMNs from spontaneous apoptosis. Thus, apoptosis of aged PMNs can be modulated by signaling through @entity8 , which may occur in @entity0 with PMN-binding anti- @entity8 autoantibodies.

title: Cross-linking of @entity0 XXXX induces the production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by polymorphonuclear neutrophils.

answer: @entity8


abstract: We have reported that @entity0 autoantibodies reacting with the polymorphonuclear neutrophil (PMN)-anchored @entity8 ( @entity9 ) protect these cells from spontaneous apoptosis. In this study, we used anti- @entity9 F(ab')(2) to delineate the mechanism(s) whereby the PMN life span is extended. As documented using four methods, @entity9 cross-linking impeded spontaneous apoptosis, whereas anti- @entity5 F(ab')(2) exerted no effect. Incubation of PMNs with anti- @entity9 prevented the up-regulation of @entity12 integrins, particularly @entity11 , which is the alpha-chain of complement receptor type 3, but also @entity5 , which is its beta-chain, as well as @entity4 and @entity7 . Anti- @entity9 -conditioned supernatant of PMNs diminished the percentage of @entity10 -binding fresh PMNs after another 18 h in culture, whereas the negative control anti- @entity5 had no effect. The expression of mRNA for @entity3 and @entity6 was induced by anti- @entity9 , followed by the release of @entity3 and @entity6 in a dose-dependent manner. Anti- @entity3 and anti- @entity6 mAbs abrogated the antiapoptotic effect of the related growth factors. The delay in apoptosis was accompanied by a down-regulated expression of @entity2 , and a partial reduction of @entity1 activity. These data suggest an autocrine involvement of anti- @entity9 -induced survival factors in the rescue of PMNs from spontaneous apoptosis. Thus, apoptosis of aged PMNs can be modulated by signaling through @entity8 , which may occur in @entity0 with PMN-binding anti- @entity8 autoantibodies.

title: Cross-linking of XXXX @entity8 induces the production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by polymorphonuclear neutrophils.

answer: @entity0


abstract: OBJECTIVE: @entity11 imbalance is often found in @entity0 with @entity3 , and this imbalance is associated with @entity10 resistance. However, the mechanism underlying the relationship between @entity11 imbalance and @entity10 resistance remains unclear. We evaluated serum @entity11 concentrations in @entity0 with @entity7 to determine if any of the levels of @entity6 were associated with the biochemical markers and @entity3 stage of @entity7 ( @entity7 ). METHODS: In 137 @entity0 with @entity7 who underwent liver biopsy, plasma levels of branched-chain @entity11 (BCAA), @entity13 ( @entity15 ), and the BCAA-to- @entity15 ratio values were determined using mass spectroscopy. These values were then assessed for associations with @entity3 stage, anthropometric markers (age, sex, and body mass index), biochemical markers ( @entity12 aminotransferase, @entity14 aminotransferase, y-glutamyl transpeptidase, albumin, platelet count, total @entity4 , @entity9 , low-density lipoprotein @entity4 , and glycosylated hemoglobin), and relevant disease-specific biomarkers (homeostasis model assessment of @entity10 resistance [HOMA-IR], serum @entity2 , ferritin, leptin, @entity5 , high-sensitivity C-reactive protein, and hyaluronic acid). RESULTS: Serum albumin levels, plasma BCAA levels, and BCAA-to- @entity15 ratio values were negatively associated with the @entity3 stage. In contrast, @entity15 levels increased with increasing @entity1 . @entity15 levels were also correlated with HOMA-IR results. CONCLUSION: Plasma BCAA levels in @entity0 with @entity7 decreased with increasing @entity8 , while @entity15 levels increased with increasing fibrotic stage. These results suggest that @entity11 imbalance and @entity10 resistance are intimately involved in a complex pathogenic mechanism for @entity7 .

title: XXXX levels are associated with @entity10 resistance in @entity0 with @entity7 .

answer: @entity13


abstract: OBJECTIVE: @entity11 imbalance is often found in @entity0 with @entity3 , and this imbalance is associated with @entity10 resistance. However, the mechanism underlying the relationship between @entity11 imbalance and @entity10 resistance remains unclear. We evaluated serum @entity11 concentrations in @entity0 with @entity7 to determine if any of the levels of @entity6 were associated with the biochemical markers and @entity3 stage of @entity7 ( @entity7 ). METHODS: In 137 @entity0 with @entity7 who underwent liver biopsy, plasma levels of branched-chain @entity11 (BCAA), @entity13 ( @entity15 ), and the BCAA-to- @entity15 ratio values were determined using mass spectroscopy. These values were then assessed for associations with @entity3 stage, anthropometric markers (age, sex, and body mass index), biochemical markers ( @entity12 aminotransferase, @entity14 aminotransferase, y-glutamyl transpeptidase, albumin, platelet count, total @entity4 , @entity9 , low-density lipoprotein @entity4 , and glycosylated hemoglobin), and relevant disease-specific biomarkers (homeostasis model assessment of @entity10 resistance [HOMA-IR], serum @entity2 , ferritin, leptin, @entity5 , high-sensitivity C-reactive protein, and hyaluronic acid). RESULTS: Serum albumin levels, plasma BCAA levels, and BCAA-to- @entity15 ratio values were negatively associated with the @entity3 stage. In contrast, @entity15 levels increased with increasing @entity1 . @entity15 levels were also correlated with HOMA-IR results. CONCLUSION: Plasma BCAA levels in @entity0 with @entity7 decreased with increasing @entity8 , while @entity15 levels increased with increasing fibrotic stage. These results suggest that @entity11 imbalance and @entity10 resistance are intimately involved in a complex pathogenic mechanism for @entity7 .

title: @entity13 levels are associated with @entity10 resistance in @entity0 with XXXX .

answer: @entity7


abstract: OBJECTIVE: @entity11 imbalance is often found in @entity0 with @entity3 , and this imbalance is associated with @entity10 resistance. However, the mechanism underlying the relationship between @entity11 imbalance and @entity10 resistance remains unclear. We evaluated serum @entity11 concentrations in @entity0 with @entity7 to determine if any of the levels of @entity6 were associated with the biochemical markers and @entity3 stage of @entity7 ( @entity7 ). METHODS: In 137 @entity0 with @entity7 who underwent liver biopsy, plasma levels of branched-chain @entity11 (BCAA), @entity13 ( @entity15 ), and the BCAA-to- @entity15 ratio values were determined using mass spectroscopy. These values were then assessed for associations with @entity3 stage, anthropometric markers (age, sex, and body mass index), biochemical markers ( @entity12 aminotransferase, @entity14 aminotransferase, y-glutamyl transpeptidase, albumin, platelet count, total @entity4 , @entity9 , low-density lipoprotein @entity4 , and glycosylated hemoglobin), and relevant disease-specific biomarkers (homeostasis model assessment of @entity10 resistance [HOMA-IR], serum @entity2 , ferritin, leptin, @entity5 , high-sensitivity C-reactive protein, and hyaluronic acid). RESULTS: Serum albumin levels, plasma BCAA levels, and BCAA-to- @entity15 ratio values were negatively associated with the @entity3 stage. In contrast, @entity15 levels increased with increasing @entity1 . @entity15 levels were also correlated with HOMA-IR results. CONCLUSION: Plasma BCAA levels in @entity0 with @entity7 decreased with increasing @entity8 , while @entity15 levels increased with increasing fibrotic stage. These results suggest that @entity11 imbalance and @entity10 resistance are intimately involved in a complex pathogenic mechanism for @entity7 .

title: @entity13 levels are associated with XXXX resistance in @entity0 with @entity7 .

answer: @entity10


abstract: OBJECTIVE: @entity11 imbalance is often found in @entity0 with @entity3 , and this imbalance is associated with @entity10 resistance. However, the mechanism underlying the relationship between @entity11 imbalance and @entity10 resistance remains unclear. We evaluated serum @entity11 concentrations in @entity0 with @entity7 to determine if any of the levels of @entity6 were associated with the biochemical markers and @entity3 stage of @entity7 ( @entity7 ). METHODS: In 137 @entity0 with @entity7 who underwent liver biopsy, plasma levels of branched-chain @entity11 (BCAA), @entity13 ( @entity15 ), and the BCAA-to- @entity15 ratio values were determined using mass spectroscopy. These values were then assessed for associations with @entity3 stage, anthropometric markers (age, sex, and body mass index), biochemical markers ( @entity12 aminotransferase, @entity14 aminotransferase, y-glutamyl transpeptidase, albumin, platelet count, total @entity4 , @entity9 , low-density lipoprotein @entity4 , and glycosylated hemoglobin), and relevant disease-specific biomarkers (homeostasis model assessment of @entity10 resistance [HOMA-IR], serum @entity2 , ferritin, leptin, @entity5 , high-sensitivity C-reactive protein, and hyaluronic acid). RESULTS: Serum albumin levels, plasma BCAA levels, and BCAA-to- @entity15 ratio values were negatively associated with the @entity3 stage. In contrast, @entity15 levels increased with increasing @entity1 . @entity15 levels were also correlated with HOMA-IR results. CONCLUSION: Plasma BCAA levels in @entity0 with @entity7 decreased with increasing @entity8 , while @entity15 levels increased with increasing fibrotic stage. These results suggest that @entity11 imbalance and @entity10 resistance are intimately involved in a complex pathogenic mechanism for @entity7 .

title: @entity13 levels are associated with @entity10 resistance in XXXX with @entity7 .

answer: @entity0


abstract: OBJECTIVE: To describe a case of crossed @entity9 that was diagnosed in a 52-year-old @entity0 who had consulted for @entity4 associated with @entity5 . METHODS: @entity0 evaluation included hematological, hormonal, cytogenetic and imaging studies. An exploratory operation was also performed. RESULTS: The hematological, hormonal and cytogenetic studies gave normal results. There were no urinary tract abnormalities in the intravenous urography; retrograde urethrography disclosed a narrow duct behind the urethra that ascended towards the left inguinal duct and divided into two epididymides after reaching the scrotum. Surgical exploration showed two testes in the left scrotal pouch that were biopsied. Histological examination revealed an almost complete hyalinization of the tubular wall with no germ cells within the tubules. CONCLUSIONS: Crossed @entity9 is one of the most uncommon @entity2 and is often associated with other disorders such as @entity3 , @entity7 , @entity8 and @entity6 . Like all dysgenetic testes, progression to @entity1 is relatively frequent. The foregoing should be remembered when dealing with these @entity0 .

title: [Transverse XXXX . A review of the literature and a case report].

answer: @entity9


abstract: PURPOSE: Biopsies taken 2 years after radiotherapy of @entity2 indicate @entity1 cells in 20-60% of cases, and the prognosis for these @entity0 is unfavorable. More precise methods of localization of the prostate are desirable to increase the dose to the @entity2 and minimize the volume of adjacent sensitive tissues that are currently included in the planning target volume. We have sought a method to more accurately locate the prostate at the time of treatment, allowing a reduction of the volume of rectum and bladder included in the high dose region during dose escalation. METHODS AND RESULTS: We have developed a new technique using a special urethral catheter (patent pending), containing markers that can be visualized by the radiotherapy machine for accurate positioning of the prostate. The catheter is used throughout the treatment planning procedure and the isocenter is placed on one of the markers. On the treatment couch the markers are visualized on port-films and with portal imaging immediately before dose delivery. A beam-center-marker on the accelerator makes it possible to adjust the isocenter position to within 1 mm, giving very high precision, independent of external fixation. The technique involves a simple @entity0 setup. The method has been tested in five @entity0 with conventional dose level (70 Gy) and in 24 @entity0 in the first Scandinavian dose escalation study with external beam radiotherapy. No increase in acute side-effects was observed. CONCLUSION: With the new high precision conformal radiotherapy (HPCRT) technique we have developed a technique that allows us to increase the dose to the prostate without excessive side effects. The method reduces the uncertainties in prostate localization, is easy to handle, and feasible in routine treatment.

title: High-precision conformal radiotherapy (HPCRT) of XXXX --a new technique for exact positioning of the prostate at the time of treatment.

answer: @entity2


abstract: BACKGROUND AND PURPOSE: To determine the percentage of complete responders and the resectability rate for @entity0 with locally advanced @entity3 treated by @entity4 ( @entity4 ) infusional chemotherapy and pelvic radiation. MATERIALS AND METHODS: Between October 1992 and June 1996, 29 @entity0 with a diagnosis of locally advanced unresectable @entity2 received preoperative 5 FU by continuous intravenous infusion at a dose of 225 mg/m2/day concurrent with pelvic radiation (median 54 Gy/28 fractions). All @entity0 were clinical stage T4 on the bases of organ invasion or @entity2 fixation. Median time for surgical resection was 6 weeks. RESULTS: Median follow-up for the group was 28 months (range 5-57 months). Six @entity0 were felt to be persistently unresectable or developed distant @entity1 and did not undergo surgical resection. Of the 29 @entity0 , 23 proceeded to surgery, 18 were resectable for cure, 13 by abdominoperineal resection, 3 by anterior resection and 2 by local excision. Of the 29 @entity0 , 4 (13%) had a complete response, and 90% were clinically downstaged. Of the 18 resected @entity0 , 1 has died of his disease, 17 are alive, and 15 disease-free. The regimen was well tolerated; there was only one treatment-related complication, a wound dehiscence. CONCLUSION: The combination of 5 FU infusion and pelvic radiation in the management of locally advanced @entity2 is well tolerated and provides a baseline for comparison purposes with future combinations of newer systemic agents and radiation.

title: Preoperative radiation with concurrent XXXX continuous infusion for locally advanced unresectable @entity2 .

answer: @entity4


abstract: BACKGROUND AND PURPOSE: To determine the percentage of complete responders and the resectability rate for @entity0 with locally advanced @entity3 treated by @entity4 ( @entity4 ) infusional chemotherapy and pelvic radiation. MATERIALS AND METHODS: Between October 1992 and June 1996, 29 @entity0 with a diagnosis of locally advanced unresectable @entity2 received preoperative 5 FU by continuous intravenous infusion at a dose of 225 mg/m2/day concurrent with pelvic radiation (median 54 Gy/28 fractions). All @entity0 were clinical stage T4 on the bases of organ invasion or @entity2 fixation. Median time for surgical resection was 6 weeks. RESULTS: Median follow-up for the group was 28 months (range 5-57 months). Six @entity0 were felt to be persistently unresectable or developed distant @entity1 and did not undergo surgical resection. Of the 29 @entity0 , 23 proceeded to surgery, 18 were resectable for cure, 13 by abdominoperineal resection, 3 by anterior resection and 2 by local excision. Of the 29 @entity0 , 4 (13%) had a complete response, and 90% were clinically downstaged. Of the 18 resected @entity0 , 1 has died of his disease, 17 are alive, and 15 disease-free. The regimen was well tolerated; there was only one treatment-related complication, a wound dehiscence. CONCLUSION: The combination of 5 FU infusion and pelvic radiation in the management of locally advanced @entity2 is well tolerated and provides a baseline for comparison purposes with future combinations of newer systemic agents and radiation.

title: Preoperative radiation with concurrent @entity4 continuous infusion for locally advanced unresectable XXXX .

answer: @entity2


abstract: BACKGROUND: The early detection of @entity2 helps guide decisions regarding optimal transfusion management during cardiac surgery. This study aimed to determine whether rotational thromboelastometry (ROTEM) analysis during cardiopulmonary bypass (CPB) could predict @entity1 and @entity4 after CPB. METHODS: We analyzed 138 cardiac surgical @entity0 for whom ROTEM tests and conventional laboratory tests were performed simultaneously both during and after CPB. An extrinsically activated ROTEM test (EXTEM), a fibrin-specific ROTEM test (FIBTEM) and PLTEM calculated by subtracting FIBTEM from EXTEM were evaluated. Correlations between clot amplitude at 10 min (A10), maximal clot firmness, platelet count, and @entity3 concentrations at each time point were calculated. A receiver operating characteristic analysis with area under the curve (AUC) was used to assess the thresholds of EXTEM, PLTEM and FIBTEM parameters during CPB and for predicting @entity1 and @entity4 after weaning of CPB. RESULTS: The A10 on EXTEM, PLTEM, and FIBTEM during CPB showed a good correlation with platelet counts (r = 0.622 on EXTEM and r = 0.637 on PLTEM; P < 0.0001 for each value) and @entity3 levels (r = 0.780; P < 0.0001) after CPB. A10 on a FIBTEM threshold of 8 mm during the CPB predicted a @entity3 concentration < 150 mg/dl (AUC = 0.853) after CPB. Additionally, the threshold level of A10 on EXTEM during CPB for predicting platelet counts < 100,000 /  l after CPB was 42 mm (AUC = 0.768). CONCLUSIONS: EXTEM, PLTEM, and FIBTEM parameters during CPB may be useful for predicting @entity1 and @entity4 after weaning of CPB.

title: Predictive value of rotational thromboelastometry during cardiopulmonary bypass for XXXX and @entity4 after weaning of cardiopulmonary bypass.

answer: @entity1


abstract: BACKGROUND: The early detection of @entity2 helps guide decisions regarding optimal transfusion management during cardiac surgery. This study aimed to determine whether rotational thromboelastometry (ROTEM) analysis during cardiopulmonary bypass (CPB) could predict @entity1 and @entity4 after CPB. METHODS: We analyzed 138 cardiac surgical @entity0 for whom ROTEM tests and conventional laboratory tests were performed simultaneously both during and after CPB. An extrinsically activated ROTEM test (EXTEM), a fibrin-specific ROTEM test (FIBTEM) and PLTEM calculated by subtracting FIBTEM from EXTEM were evaluated. Correlations between clot amplitude at 10 min (A10), maximal clot firmness, platelet count, and @entity3 concentrations at each time point were calculated. A receiver operating characteristic analysis with area under the curve (AUC) was used to assess the thresholds of EXTEM, PLTEM and FIBTEM parameters during CPB and for predicting @entity1 and @entity4 after weaning of CPB. RESULTS: The A10 on EXTEM, PLTEM, and FIBTEM during CPB showed a good correlation with platelet counts (r = 0.622 on EXTEM and r = 0.637 on PLTEM; P < 0.0001 for each value) and @entity3 levels (r = 0.780; P < 0.0001) after CPB. A10 on a FIBTEM threshold of 8 mm during the CPB predicted a @entity3 concentration < 150 mg/dl (AUC = 0.853) after CPB. Additionally, the threshold level of A10 on EXTEM during CPB for predicting platelet counts < 100,000 /  l after CPB was 42 mm (AUC = 0.768). CONCLUSIONS: EXTEM, PLTEM, and FIBTEM parameters during CPB may be useful for predicting @entity1 and @entity4 after weaning of CPB.

title: Predictive value of rotational thromboelastometry during cardiopulmonary bypass for @entity1 and XXXX after weaning of cardiopulmonary bypass.

answer: @entity4


abstract: INTRODUCTION: @entity3 (VA) is a widely used antiepileptic drug. Because of its pharmacokinetic variability and the influence of intrinsic and extrinsic factors such as the treatment compliance, VA therapeutic drug monitoring (TDM) is recommended in @entity0 . The aim of this study is to evaluate the effect of treatment compliance and the economic level on VA @entity4 ( @entity4 ) and @entity2 rhythm in @entity0 . MATERIAL AND METHODS: A one-year prospective study (August 2008-August 2009) concerning @entity0 (age  <= 5 years) regularly treated by VA who had a VA TDM. So, 276 plasmatic samples from 238 @entity0 were collected. The @entity0 were divided in two groups as following: the group 1 (G1) presenting a good compliance and a reliable questioning and the group 2 (G2) presenting a bad compliance and a non reliable questioning. We evaluated the interindividual variability by correlating the @entity4 to the dose. Then, we divided the hole group in function of their economic levels (low-medium-high). RESULTS: Sex ratio male/female was 1.3. Median age was 5  years +/-3,9. The mean @entity4 was 62   g/mL [0.12-131   g/mL]. VA @entity4 were in the therapeutic range (TR) in 62%. @entity1 were noted in 4.2% of the @entity0 . G1 represented 70% of the @entity0 and G2, 30%. The @entity4 were in the TR in 67% of G1 and 51% of G2 (p = 0.02). There was a significant difference between the @entity4 in G1 and G2 (p = 0.02).There was no significative difference in the @entity4 in function of the economic levels. There was no correlation between @entity4 and the administered doses. The @entity2 were more spaced in @entity0 with therapeutic @entity4 than those with @entity4 in the TR (p = 0.002) and in G1than in G2 (p = 0.03). CONCLUSIONS: Compliance should be appropriate in order to optimize the TDM rule. A good compliance and a therapeutic @entity4 allow a better control of @entity2 .

title: [Therapeutic Drug Monitoring of XXXX in @entity0 :  A Prospective Study of The Effect of The Compliance and The Economic Level on the Trough Plasmatic Concentrations and @entity2 ].

answer: @entity3


abstract: INTRODUCTION: @entity3 (VA) is a widely used antiepileptic drug. Because of its pharmacokinetic variability and the influence of intrinsic and extrinsic factors such as the treatment compliance, VA therapeutic drug monitoring (TDM) is recommended in @entity0 . The aim of this study is to evaluate the effect of treatment compliance and the economic level on VA @entity4 ( @entity4 ) and @entity2 rhythm in @entity0 . MATERIAL AND METHODS: A one-year prospective study (August 2008-August 2009) concerning @entity0 (age  <= 5 years) regularly treated by VA who had a VA TDM. So, 276 plasmatic samples from 238 @entity0 were collected. The @entity0 were divided in two groups as following: the group 1 (G1) presenting a good compliance and a reliable questioning and the group 2 (G2) presenting a bad compliance and a non reliable questioning. We evaluated the interindividual variability by correlating the @entity4 to the dose. Then, we divided the hole group in function of their economic levels (low-medium-high). RESULTS: Sex ratio male/female was 1.3. Median age was 5  years +/-3,9. The mean @entity4 was 62   g/mL [0.12-131   g/mL]. VA @entity4 were in the therapeutic range (TR) in 62%. @entity1 were noted in 4.2% of the @entity0 . G1 represented 70% of the @entity0 and G2, 30%. The @entity4 were in the TR in 67% of G1 and 51% of G2 (p = 0.02). There was a significant difference between the @entity4 in G1 and G2 (p = 0.02).There was no significative difference in the @entity4 in function of the economic levels. There was no correlation between @entity4 and the administered doses. The @entity2 were more spaced in @entity0 with therapeutic @entity4 than those with @entity4 in the TR (p = 0.002) and in G1than in G2 (p = 0.03). CONCLUSIONS: Compliance should be appropriate in order to optimize the TDM rule. A good compliance and a therapeutic @entity4 allow a better control of @entity2 .

title: [Therapeutic Drug Monitoring of @entity3 in @entity0 :  A Prospective Study of The Effect of The Compliance and The Economic Level on the Trough Plasmatic Concentrations and XXXX ].

answer: @entity2


abstract: INTRODUCTION: @entity3 (VA) is a widely used antiepileptic drug. Because of its pharmacokinetic variability and the influence of intrinsic and extrinsic factors such as the treatment compliance, VA therapeutic drug monitoring (TDM) is recommended in @entity0 . The aim of this study is to evaluate the effect of treatment compliance and the economic level on VA @entity4 ( @entity4 ) and @entity2 rhythm in @entity0 . MATERIAL AND METHODS: A one-year prospective study (August 2008-August 2009) concerning @entity0 (age  <= 5 years) regularly treated by VA who had a VA TDM. So, 276 plasmatic samples from 238 @entity0 were collected. The @entity0 were divided in two groups as following: the group 1 (G1) presenting a good compliance and a reliable questioning and the group 2 (G2) presenting a bad compliance and a non reliable questioning. We evaluated the interindividual variability by correlating the @entity4 to the dose. Then, we divided the hole group in function of their economic levels (low-medium-high). RESULTS: Sex ratio male/female was 1.3. Median age was 5  years +/-3,9. The mean @entity4 was 62   g/mL [0.12-131   g/mL]. VA @entity4 were in the therapeutic range (TR) in 62%. @entity1 were noted in 4.2% of the @entity0 . G1 represented 70% of the @entity0 and G2, 30%. The @entity4 were in the TR in 67% of G1 and 51% of G2 (p = 0.02). There was a significant difference between the @entity4 in G1 and G2 (p = 0.02).There was no significative difference in the @entity4 in function of the economic levels. There was no correlation between @entity4 and the administered doses. The @entity2 were more spaced in @entity0 with therapeutic @entity4 than those with @entity4 in the TR (p = 0.002) and in G1than in G2 (p = 0.03). CONCLUSIONS: Compliance should be appropriate in order to optimize the TDM rule. A good compliance and a therapeutic @entity4 allow a better control of @entity2 .

title: [Therapeutic Drug Monitoring of @entity3 in XXXX :  A Prospective Study of The Effect of The Compliance and The Economic Level on the Trough Plasmatic Concentrations and @entity2 ].

answer: @entity0


abstract: BACKGROUND: The incidence of @entity1 in South Africa (SA) remains high, and the current screening programme has had limited success. New approaches to prevention and screening tactics are needed. OBJECTIVES: To investigate acceptance of school-based @entity2 ) vaccination, as well as the information provided, methods of obtaining consent and assent, and completion rates achieved. METHODS: Information on @entity1 and HPV vaccination was provided to 19 primary schools in Western Cape and Gauteng provinces participating in the study. @entity0 with parental consent and @entity0 assent were vaccinated during school hours at their schools. RESULTS: A total of 3 465 @entity0 were invited to receive HPV vaccine, of whom 2 046 provided written parental consent as well as @entity0 assent. At least one dose of vaccine was delivered to 2 030 @entity0 (99.2% of the consented cohort), while a total of 1 782 @entity0 received all three doses. Sufficient vaccination was achieved in 91.6% of the vaccinated cohort. Of all invited @entity0 , 56.9% in Gauteng and 50.7% in the Western Cape were sufficiently vaccinated. CONCLUSION: This implementation project demonstrated that HPV vaccination is practical and safe in SA schools. Political and community acceptance was good, and positive attitudes towards vaccination were encountered. During the study, which mimicked a governmental vaccine roll-out programme, high completion rates were achieved in spite of several challenges encountered.

title: The vaccine and @entity1 screen (VACCS) project: acceptance of XXXX vaccination in a school-based programme in two provinces of South Africa.

answer: @entity2


abstract: BACKGROUND: The incidence of @entity1 in South Africa (SA) remains high, and the current screening programme has had limited success. New approaches to prevention and screening tactics are needed. OBJECTIVES: To investigate acceptance of school-based @entity2 ) vaccination, as well as the information provided, methods of obtaining consent and assent, and completion rates achieved. METHODS: Information on @entity1 and HPV vaccination was provided to 19 primary schools in Western Cape and Gauteng provinces participating in the study. @entity0 with parental consent and @entity0 assent were vaccinated during school hours at their schools. RESULTS: A total of 3 465 @entity0 were invited to receive HPV vaccine, of whom 2 046 provided written parental consent as well as @entity0 assent. At least one dose of vaccine was delivered to 2 030 @entity0 (99.2% of the consented cohort), while a total of 1 782 @entity0 received all three doses. Sufficient vaccination was achieved in 91.6% of the vaccinated cohort. Of all invited @entity0 , 56.9% in Gauteng and 50.7% in the Western Cape were sufficiently vaccinated. CONCLUSION: This implementation project demonstrated that HPV vaccination is practical and safe in SA schools. Political and community acceptance was good, and positive attitudes towards vaccination were encountered. During the study, which mimicked a governmental vaccine roll-out programme, high completion rates were achieved in spite of several challenges encountered.

title: The vaccine and XXXX screen (VACCS) project: acceptance of @entity2 vaccination in a school-based programme in two provinces of South Africa.

answer: @entity1


abstract: Despite many advances in the management of @entity8 ( @entity8 ), the condition carries a mortality rate of 40-50% usually consequent to @entity5 and/or persistent @entity1 . Several centers have reported improved survival with preoperative stabilization and delayed surgery, which is now an accepted method of management. This is a retrospective analysis of all neonates with @entity6 at birth due to @entity8 who were treated at our institution with neither extracorporeal membrane oxygenation nor @entity7 being used. The medical records of all neonates with @entity8 and @entity6 at birth who were treated at this institution from August 1, 1992 through @entity9 , 1997 were reviewed. There were 21 @entity0 , 11 male and 10 female. There were 17 full-term and 4 premature @entity0 ; two premature @entity0 at 30 and 34 weeks' gestation were not resuscitated because of severe associated @entity2 . Surgery was performed from 5 to 144 hr (mean 45 hr) in 18 @entity0 . One @entity0 died during preoperative stabilization from severe @entity5 and @entity1 and one @entity0 died postoperatively from the same conditions. Seventeen of 19 @entity0 (89.5%) survived and were discharged home. Three @entity0 (17.6%) who failed to thrive due to severe @entity4 ( @entity4 ) required fundoplication. Eleven @entity0 (64.7%) who had @entity3 proven by blood culture responded satisfactorily to appropriate antibiotics. Preoperative stabilization and delayed surgery has been a satisfactory form of management in our series. The significant complication was @entity3 , which must be addressed.

title: XXXX : experience with preoperative stabilization and delayed surgery without ECMO and inhaled @entity7 .

answer: @entity8


abstract: Despite many advances in the management of @entity8 ( @entity8 ), the condition carries a mortality rate of 40-50% usually consequent to @entity5 and/or persistent @entity1 . Several centers have reported improved survival with preoperative stabilization and delayed surgery, which is now an accepted method of management. This is a retrospective analysis of all neonates with @entity6 at birth due to @entity8 who were treated at our institution with neither extracorporeal membrane oxygenation nor @entity7 being used. The medical records of all neonates with @entity8 and @entity6 at birth who were treated at this institution from August 1, 1992 through @entity9 , 1997 were reviewed. There were 21 @entity0 , 11 male and 10 female. There were 17 full-term and 4 premature @entity0 ; two premature @entity0 at 30 and 34 weeks' gestation were not resuscitated because of severe associated @entity2 . Surgery was performed from 5 to 144 hr (mean 45 hr) in 18 @entity0 . One @entity0 died during preoperative stabilization from severe @entity5 and @entity1 and one @entity0 died postoperatively from the same conditions. Seventeen of 19 @entity0 (89.5%) survived and were discharged home. Three @entity0 (17.6%) who failed to thrive due to severe @entity4 ( @entity4 ) required fundoplication. Eleven @entity0 (64.7%) who had @entity3 proven by blood culture responded satisfactorily to appropriate antibiotics. Preoperative stabilization and delayed surgery has been a satisfactory form of management in our series. The significant complication was @entity3 , which must be addressed.

title: @entity8 : experience with preoperative stabilization and delayed surgery without ECMO and inhaled XXXX .

answer: @entity7


abstract: BACKGROUND: A thorough understanding of the @entity0 's genotype and their functional response to a medication is necessary for improving event free survival. Several outcome studies support this view particularly if the @entity0 is to be started on @entity4 due to the prevalence of @entity4 resistance. Such guided therapy has reduced the incidence of Major Adverse @entity1 (MACE) after stent implantation. METHODS: Between August 2013 and August 2014, 200 @entity0 with @entity2 undergoing percutaneous coronary intervention (PCI) were prescribed any one of the anti-platelet medications such as @entity4 , @entity6 or @entity7 and offered testing to detect @entity8 gene mutations along with a platelet reactivity assay (PRA). Intended outcome was modification of anti-platelet therapy defined as either dose escalation of @entity4 or replacement of @entity4 with @entity6 or @entity7 for the @entity0 in @entity4 arm, and replacement of @entity7 or @entity6 with @entity4 if those @entity0 were non-carrier of mutant genes and also if they demonstrated @entity3 tendencies in the @entity7 and @entity6 arms. CONCLUSION: @entity4 resistance was observed to be 16.5% in our study population. PRA was useful in monitoring the efficacy of @entity5 . By having this test, one can be safely maintained on @entity4 in non-carriers, or with increased dose of @entity4 in intermediate metabolizers or with newer drugs such as @entity7 or @entity6 in poor metabolizers. @entity0 on @entity7 and @entity6 identified as non-carriers of gene mutations for @entity4 metabolism could be offered @entity4 resulting in economic benefits to the @entity0 . @entity0 at high risk of @entity3 were also identified by the PRA.

title: A study on the impact of XXXX genotype and platelet reactivity assay on @entity0 undergoing PCI.

answer: @entity8


abstract: BACKGROUND: A thorough understanding of the @entity0 's genotype and their functional response to a medication is necessary for improving event free survival. Several outcome studies support this view particularly if the @entity0 is to be started on @entity4 due to the prevalence of @entity4 resistance. Such guided therapy has reduced the incidence of Major Adverse @entity1 (MACE) after stent implantation. METHODS: Between August 2013 and August 2014, 200 @entity0 with @entity2 undergoing percutaneous coronary intervention (PCI) were prescribed any one of the anti-platelet medications such as @entity4 , @entity6 or @entity7 and offered testing to detect @entity8 gene mutations along with a platelet reactivity assay (PRA). Intended outcome was modification of anti-platelet therapy defined as either dose escalation of @entity4 or replacement of @entity4 with @entity6 or @entity7 for the @entity0 in @entity4 arm, and replacement of @entity7 or @entity6 with @entity4 if those @entity0 were non-carrier of mutant genes and also if they demonstrated @entity3 tendencies in the @entity7 and @entity6 arms. CONCLUSION: @entity4 resistance was observed to be 16.5% in our study population. PRA was useful in monitoring the efficacy of @entity5 . By having this test, one can be safely maintained on @entity4 in non-carriers, or with increased dose of @entity4 in intermediate metabolizers or with newer drugs such as @entity7 or @entity6 in poor metabolizers. @entity0 on @entity7 and @entity6 identified as non-carriers of gene mutations for @entity4 metabolism could be offered @entity4 resulting in economic benefits to the @entity0 . @entity0 at high risk of @entity3 were also identified by the PRA.

title: A study on the impact of @entity8 genotype and platelet reactivity assay on XXXX undergoing PCI.

answer: @entity0


abstract: This study was carried out to assess the efficacy of 0.025% and 0.05% @entity5 eye-drops in @entity0 with @entity1 of > or = 1 year's duration. A total of 151 @entity0 received 0.025% or 0.05% @entity5 eye-drops or placebo b.i.d. for 14 days according to a double-blind, randomized, placebo-controlled, parallel-dosing design; 129 @entity0 completed the study as planned. The three target symptoms, scored on 4-point scales, were @entity2 , lacrimation, and @entity4 ; responders were @entity0 whose symptom sum score decreased by > or = 3 from a baseline score of > or = 6 by day 3. Mean scores of these and five other symptoms were recorded also on days 7 and 14, and @entity0 kept daily diaries of the three main symptoms and swollen eyelids. Responder rates were 73% for 0.025% (P=0.115 vs placebo) and 82% for 0.05% @entity5 eye-drops (P=0.011 vs placebo) and 56% for placebo. The time courses of the mean (investigators' and @entity0 ') scores for the three main symptoms reflected the dose-dependent effect of @entity5 eye-drops. One @entity0 each from the two @entity5 groups and three from the placebo group withdrew because of inefficacy. @entity3 were reported by 14 and 24 @entity0 receiving 0.025% and 0.05% @entity5 eye-drops, respectively, and by eight placebo @entity0 . These reactions were mainly slight application site reactions and taste perversion (bitter or unpleasant taste). @entity5 eye-drops are effective and well tolerated at a dose of 0.05% for the treatment of @entity1 .

title: XXXX eye-drops in @entity1 or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study.

answer: @entity5


abstract: This study was carried out to assess the efficacy of 0.025% and 0.05% @entity5 eye-drops in @entity0 with @entity1 of > or = 1 year's duration. A total of 151 @entity0 received 0.025% or 0.05% @entity5 eye-drops or placebo b.i.d. for 14 days according to a double-blind, randomized, placebo-controlled, parallel-dosing design; 129 @entity0 completed the study as planned. The three target symptoms, scored on 4-point scales, were @entity2 , lacrimation, and @entity4 ; responders were @entity0 whose symptom sum score decreased by > or = 3 from a baseline score of > or = 6 by day 3. Mean scores of these and five other symptoms were recorded also on days 7 and 14, and @entity0 kept daily diaries of the three main symptoms and swollen eyelids. Responder rates were 73% for 0.025% (P=0.115 vs placebo) and 82% for 0.05% @entity5 eye-drops (P=0.011 vs placebo) and 56% for placebo. The time courses of the mean (investigators' and @entity0 ') scores for the three main symptoms reflected the dose-dependent effect of @entity5 eye-drops. One @entity0 each from the two @entity5 groups and three from the placebo group withdrew because of inefficacy. @entity3 were reported by 14 and 24 @entity0 receiving 0.025% and 0.05% @entity5 eye-drops, respectively, and by eight placebo @entity0 . These reactions were mainly slight application site reactions and taste perversion (bitter or unpleasant taste). @entity5 eye-drops are effective and well tolerated at a dose of 0.05% for the treatment of @entity1 .

title: @entity5 eye-drops in XXXX or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study.

answer: @entity1


abstract: Therapeutic strategies for @entity5 are directed to induction of differentiation and apoptosis as well as growth inhibition. One of the key antileukemic agents, @entity7 (ara C), is clinically applied according to these therapeutic aims. However, the molecular effects of 0.1 microg/ml of ara C, a concentration that corresponds to the serum level in @entity5 @entity0 on a conventional dose of ara C, have not been well disclosed. Here, we addressed these issues using K562 cells which derived from a blastic crisis of @entity6 . DNA synthesis of treated cells was suppressed from 1-6 h. But, it recovered at 12 h and no further inhibition was observed. The number of cells was not decreased but DNA fragmentation was observed at 72 h. The number of erythroid-differentiated cells also increased to 30% at 72 h. Along with treatment, no marked alteration of mRNAs for cell cycle-regulating genes was found and the @entity3 gene product remained hyperphosphorylated throughout treatment. The expression of mRNAs for apoptosis-regulating genes also remained unchanged, except for slight down-regulation of @entity2 . @entity1 protein was not found later than 48 h, and Max mRNA was downregulated. @entity4 was immediately induced, followed by the fluctuated expression level along with treatment. These findings suggest that the 0.1 microg/ml ara C changed the proliferation, differentiation and death of K562 cells in a biphasic manner. In the early phase, DNA synthesis was inhibited without altering the expression of cell cycle regulating-genes. In the latter phase, cell death and erythroid- differentiation occurred in accordance with the down-regulation of @entity1 .

title: Biological effects of a relatively low concentration of XXXX in K562 cells: alterations of the cell cycle, erythroid-differentiation, and apoptosis.

answer: @entity7


abstract: UNASSIGNED: Nanoparticle uptake and distribution to solid @entity0 are limited by reticuloendothelial system systemic filtering and transport limitations induced by irregular intra-tumoral vascularization. Although vascular enhanced permeability and retention can aid targeting, high interstitial fluid pressure and dense extracellular matrix may hinder local penetration. Extravascular diffusivity depends upon nanoparticle size, surface modifications, and tissue vascularization. Gold nanoparticles functionalized with biologically-compatible layers may achieve improved uptake and distribution while enabling @entity2 through synergistic combination of chemotherapy and thermal ablation. Evaluation of nanoparticle uptake in vivo remains difficult, as detection methods are limited. We employ hyperspectral imaging of histology sections to analyze uptake and distribution of @entity5 -coated @entity7 gold nanoparticles (CGN) and @entity6 -gold nanoshells (SGN) after tail-vein injection in @entity1 bearing orthotopic pancreatic @entity3 . For CGN, the liver and @entity0 showed 26.5  8.2 and 23.3  4.1 particles/100 m2 within 10 m from the nearest source and few nanoparticles beyond 50 m, respectively. The spleen had 35.5  9.3 particles/100 m2 within 10 m with penetration also limited to 50 m. For SGN, the liver showed 31.1  4.1 particles/100 m2 within 10 m of the nearest source with penetration hindered beyond 30 m. The spleen and @entity0 showed uptake of 22.1  6.2 and 15.8  6.1 particles/100 m2 within 10 m, respectively, with penetration similarly hindered. CGH average concentration (nanoparticles/ m2) was 1.09  0.14 in the liver, 0.74  0.12 in the spleen, and 0.43  0.07 in the @entity0 . SGN average concentration (nanoparticles/ m2) was 0.43  0.07 in the liver, 0.30  0.06 in the spleen, and 0.20  0.04 in the @entity0 . Hyperspectral imaging of histology sections enables analysis of @entity5 -coated gold-based nanoparticles in @entity4 with the goal to improve nanotherapeutic efficacy.

title: Detection of @entity5 -Coated Gold Nanoparticles in Orthotopic XXXX using Hyperspectral Imaging.

answer: @entity4


abstract: UNASSIGNED: Nanoparticle uptake and distribution to solid @entity0 are limited by reticuloendothelial system systemic filtering and transport limitations induced by irregular intra-tumoral vascularization. Although vascular enhanced permeability and retention can aid targeting, high interstitial fluid pressure and dense extracellular matrix may hinder local penetration. Extravascular diffusivity depends upon nanoparticle size, surface modifications, and tissue vascularization. Gold nanoparticles functionalized with biologically-compatible layers may achieve improved uptake and distribution while enabling @entity2 through synergistic combination of chemotherapy and thermal ablation. Evaluation of nanoparticle uptake in vivo remains difficult, as detection methods are limited. We employ hyperspectral imaging of histology sections to analyze uptake and distribution of @entity5 -coated @entity7 gold nanoparticles (CGN) and @entity6 -gold nanoshells (SGN) after tail-vein injection in @entity1 bearing orthotopic pancreatic @entity3 . For CGN, the liver and @entity0 showed 26.5  8.2 and 23.3  4.1 particles/100 m2 within 10 m from the nearest source and few nanoparticles beyond 50 m, respectively. The spleen had 35.5  9.3 particles/100 m2 within 10 m with penetration also limited to 50 m. For SGN, the liver showed 31.1  4.1 particles/100 m2 within 10 m of the nearest source with penetration hindered beyond 30 m. The spleen and @entity0 showed uptake of 22.1  6.2 and 15.8  6.1 particles/100 m2 within 10 m, respectively, with penetration similarly hindered. CGH average concentration (nanoparticles/ m2) was 1.09  0.14 in the liver, 0.74  0.12 in the spleen, and 0.43  0.07 in the @entity0 . SGN average concentration (nanoparticles/ m2) was 0.43  0.07 in the liver, 0.30  0.06 in the spleen, and 0.20  0.04 in the @entity0 . Hyperspectral imaging of histology sections enables analysis of @entity5 -coated gold-based nanoparticles in @entity4 with the goal to improve nanotherapeutic efficacy.

title: Detection of XXXX -Coated Gold Nanoparticles in Orthotopic @entity4 using Hyperspectral Imaging.

answer: @entity5


abstract: This report provides the first evidence for the existence of two distinct types of @entity2 -binding protein (FABP) in cardiac tissue of vertebrates. Four species of Antarctic teleost fish ( @entity4 , Cryodraco antarcticus, Gobionotothen gibberifrons and @entity3 ) exhibited two FABP mRNAs of 1. 0 kb and 0.8 kb, which we have termed Hh-FABP and Had-FABP (isolated from Heart tissue, with similarity to @entity0 heart-type FABP or @entity0 adipose-type FABP respectively). These FABP types appear to be products of distinct genes. Both FABP transcripts were abundant in cardiac and aerobic pectoral muscle. However, relative abundance of the two types varied distinctly among other tissues such as kidney, brain, spleen and white muscle. Neither FABP type was expressed in liver or intestine. The coding regions of Hh-FABP and Had-FABP cDNAs from the same species are only approximately 60% identical with one another. However, homologues of each FABP species, which exhibit >98% identity to their respective types, were isolated from three other Antarctic teleosts. Phylogenetic analysis of aligned @entity1 sequences places Hh-FABP with other vertebrate heart-type FABPs, and Had with adipose/cutaneous FABPs. Expression of two distinct FABPs in cardiac tissue of Antarctic teleosts may be related to their ability to both utilize @entity2 as the primary metabolic fuel and to store lipid intracellularly.

title: Two distinct types of XXXX -binding protein are expressed in heart ventricle of Antarctic teleost fishes.

answer: @entity2


abstract: BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is frequently responsible for symptoms in @entity5 ( @entity5 ). Medical therapy is often not sufficient to control these symptoms, and surgical myotomy-myomectomy is required. METHODS AND RESULTS: We enrolled 33 symptomatic @entity0 with @entity5 and obstruction (>/=40 mm Hg gradient at rest or >/=60 mm Hg @entity1 -provoked). By contrast echocardiography, the bulging septum was localized and infarcted by injection of 2 to 5 mL of absolute @entity4 into the septal artery(ies) supplying the hypertrophied area. Baseline echocardiograms with Doppler, myocardial perfusion tomograms, and treadmill exercise or pharmacological testing were compared with those at 6 weeks and 6 months. The mean rise in @entity3 kinase was 1964+/-796 U. All @entity0 experienced symptomatic relief; NYHA class decreased from 3. 0+/-0.5 to 0.9+/-0.6 (P<0.001). Exercise time increased from 286+/-193 to 421+/-181 seconds (P=0.03). The resting and @entity1 -provoked gradient decreased from 49+/-33 and 96+/-34 mm Hg to 9+/-19 (P<0.001) and 24+/-31 mm Hg (P<0.001), respectively. Echocardiograms repeated at 6 weeks after the procedure showed a 28% reduction in septal thickness and 17% reduction in left ventricular mass. Myocardial perfusion imaging showed a "septal amputation pattern," with @entity6 in the upper and middle septal areas. Complete @entity2 developed in 11 @entity0 , who then required permanent pacemaker implantation. CONCLUSIONS: Echocardiography-guided @entity4 septal reduction in @entity0 with @entity5 is a safe, minimally invasive procedure that provides symptomatic relief with improved hemodynamic and left ventricular parameters.

title: Echocardiography-guided @entity4 septal reduction for XXXX .

answer: @entity5


abstract: BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is frequently responsible for symptoms in @entity5 ( @entity5 ). Medical therapy is often not sufficient to control these symptoms, and surgical myotomy-myomectomy is required. METHODS AND RESULTS: We enrolled 33 symptomatic @entity0 with @entity5 and obstruction (>/=40 mm Hg gradient at rest or >/=60 mm Hg @entity1 -provoked). By contrast echocardiography, the bulging septum was localized and infarcted by injection of 2 to 5 mL of absolute @entity4 into the septal artery(ies) supplying the hypertrophied area. Baseline echocardiograms with Doppler, myocardial perfusion tomograms, and treadmill exercise or pharmacological testing were compared with those at 6 weeks and 6 months. The mean rise in @entity3 kinase was 1964+/-796 U. All @entity0 experienced symptomatic relief; NYHA class decreased from 3. 0+/-0.5 to 0.9+/-0.6 (P<0.001). Exercise time increased from 286+/-193 to 421+/-181 seconds (P=0.03). The resting and @entity1 -provoked gradient decreased from 49+/-33 and 96+/-34 mm Hg to 9+/-19 (P<0.001) and 24+/-31 mm Hg (P<0.001), respectively. Echocardiograms repeated at 6 weeks after the procedure showed a 28% reduction in septal thickness and 17% reduction in left ventricular mass. Myocardial perfusion imaging showed a "septal amputation pattern," with @entity6 in the upper and middle septal areas. Complete @entity2 developed in 11 @entity0 , who then required permanent pacemaker implantation. CONCLUSIONS: Echocardiography-guided @entity4 septal reduction in @entity0 with @entity5 is a safe, minimally invasive procedure that provides symptomatic relief with improved hemodynamic and left ventricular parameters.

title: Echocardiography-guided XXXX septal reduction for @entity5 .

answer: @entity4


abstract: BACKGROUND: Nonfasting @entity6 are similar or superior to fasting @entity6 at predicting @entity2 . However, diagnostic cut points are based on fasting @entity6 . We examined the optimal cut point for increased nonfasting @entity6 . METHODS: We obtained baseline nonfasting (<8 h since last meal) samples from 6391 @entity0 in the @entity0 's Health Study who were followed prospectively for  <=17 years. The optimal diagnostic threshold for nonfasting @entity6 , determined by logistic regression models by use of c-statistics and the Youden index (sum of sensitivity and specificity minus 1), was used to calculate hazard ratios (HRs) for incident @entity2 . Performance was compared to thresholds recommended by the @entity5 ( @entity5 ) and European guidelines. RESULTS: The optimal threshold was 175 mg/dL (1.98 mmol/L), with a c-statistic of 0.656, statistically better than the @entity5 cut point of 200 mg/dL (c-statistic 0.628). For nonfasting @entity6 above and below 175 mg/dL, after adjusting for age, @entity3 , smoking, hormone use, and menopausal status, the HR for @entity2 was 1.88 (95% CI 1.52-2.33, P < 0.001), and for @entity6 measured at 0-4 and 4-8 h since the last meal, 2.05 (1.54- 2.74) and 1.68 (1.21-2.32), respectively. We validated performance of this optimal cut point by use of 10-fold cross-validation and bootstrapping of multivariable models that included standard risk factors plus total and HDL @entity4 , @entity1 , body mass index, and @entity7 . CONCLUSIONS: In this study of middle-aged and older apparently healthy @entity0 , we identified a diagnostic threshold for nonfasting @entity8 of 175 mg/dL (1.98 mmol/L), with the potential to more accurately identify cases than the currently recommended @entity5 cut point.

title: Identifying an Optimal Cut Point for the Diagnosis of XXXX in the Nonfasting State.

answer: @entity8


abstract: BACKGROUND: Recently, attempts have been made to cure @entity2 by creating @entity0 with radiofrequency energy. Intracardiac echocardiography (ICE) offers imaging of endocardial anatomy and the ablation electrode-tissue interface not available with standard fluoroscopy. This study sought to prospectively compare fluoroscopic with ICE guidance for the creation of linear @entity0 in a @entity1 model. METHODS AND RESULTS: The creation of 3 linear @entity0 was attempted in each of 10 @entity1 , half guided by fluoroscopy alone and half by ICE. Coil-tissue contact was prospectively graded. After ablation, animals were euthanized, and the location and continuity of lesions were evaluated. ICE guidance led to a higher percentage of successful applications (P=0.02) and mean achieved temperature (P=0. 004). The contact scores of excellent, fair, and poor correlated well with successful energy delivery, mean temperature, and efficiency of heating (P<0.0001). In 25% of the blinded energy deliveries, the location, as determined by the ablation operator, differed from that of ICE. Pathological evaluation revealed improved lesion formation in the ICE-guided compared with the ICE-blinded group. Lesions were found outside the target areas in the ICE-blinded but not the ICE-guided group. CONCLUSIONS: Compared with fluoroscopy, ICE guidance improved targeting, energy delivery, and lesion formation in this @entity1 model. This study suggests that ICE guidance improves lesion formation and prevents energy delivery to potentially dangerous sites.

title: Comparative study of fluoroscopy and intracardiac echocardiographic guidance for the creation of linear XXXX .

answer: @entity0


abstract: UNASSIGNED: T cell infiltration into the CNS is a significant underlying pathogenesis in @entity3 . Several lines of evidence suggest that @entity4 dysregulation in the CNS is an important consequence of immune cell infiltration in neuroinflammatory @entity0 ; yet, the causal link between @entity2 and @entity4 dysregulation is not well understood. A major source of @entity4 release during oxidative stress is the system Xc (-) transporter; however, this mechanism has not been tested in animal models of @entity3 . We find that pharmacological and genetic inhibition of system Xc (-) attenuates chronic and relapsing-remitting @entity5 ( @entity5 ). Remarkably, pharmacological blockade of system Xc (-) 7 d after induction of @entity5 attenuated T cell infiltration into the CNS, but not T cell activation in the periphery. @entity1 harboring a @entity6 ( @entity6 ) mutation that inactivated system Xc (-) were resistant to @entity5 , corroborating a central role for system Xc (-) in mediating immune cell infiltration. We next examined the role of the system Xc (-) transporter in the CNS after immune cell infiltration. Pharmacological inhibitors of the system Xc (-) transporter administered during the first relapse in a SJL animal model of relapsing-remitting @entity5 abrogated clinical disease, @entity2 , and myelin loss. Primary coculture studies demonstrate that myelin-specific CD4(+) Th1 cells provoke microglia to release @entity4 via the system Xc (-) transporter, causing excitotoxic death to mature myelin-producing oligodendrocytes. Taken together, these studies support a novel role for the system Xc (-) transporter in mediating T cell infiltration into the CNS as well as promoting @entity0 after immune cell infiltration in @entity5 .

title: Inhibition of System Xc- Transporter Attenuates Autoimmune Inflammatory XXXX .

answer: @entity0